Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma
Sponsor: Centre Hospitalier Universitaire, Amiens
Summary
Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients. The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.
Key Details
Gender
All
Age Range
20 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2020-09-21
Completion Date
2024-01-18
Last Updated
2026-06-12
Healthy Volunteers
No
Conditions
Interventions
MEMOPTIC
Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
usual treatment of glaucoma
Patients will receive only their usual treatment of glaucoma.
Locations (1)
CHU Amiens
Amiens, France